Biologics In Focus
Introduction
Welcome once again to Lonza’s Biologics newsletter, Biologics In Focus, for our July edition.
Each month, we deliver deep analysis of industry trends, expert insights, and an overview of upcoming events—as well as the latest Lonza news and real-world customer stories.
If you haven’t already, why not subscribe and join over 85,000 people who receive automatic notifications every time we publish?
Lonza News and Updates
Patronus Biotech (Patronus) is a clinical-stage company focusing on the development, manufacturing and commercialization of novel vaccines. Patronus has announced their LYB004 herpes zoster vaccine candidate, expressed using Lonza’s CHOK1SV GS-KO? cell line and GS piggyBac? technology, has received approval to progress to clinical trials. Read the full announcement here.
Insights and Analysis
Recently, Dr. Jin Lu presented a webinar explaining how Lonza’s novel expression tools can advance bispecific antibody discovery programs.
In the session, she explained how the GS Discovery? transient expression platform could boost transient titers by ~30-fold to enable rapid early material supply and streamline the transition from discovery to stable production. You can watch the webinar on-demand here.
Our recent white paper explains how you can unlock the full potential of your antibody-drug conjugate (ADC) development with Lonza’s Ibex? Design ADC program.
It discusses new cytotoxic drug product capabilities, faster development timelines and support available from early phase services through to commercialization. Read more to find out how to accelerate your ADC projects and enhance quality, whether you need integrated or stand-alone solutions.
Technology transfer, as an integral part of a biopharmaceutical product lifecycle, is driven by manufacturing requirements to meet the clinical and commercial needs. For example, a process will be developed at a small scale, transferred via a pilot to a manufacturing facility for clinical evaluation; then, as a project matures, larger scale facilities may be required to meet commercial demand.
In this article, Lonza’s Andrew Brown, Samit Patel, and Mark Whickman discuss the downstream (i.e., the primary recovery of a biologic substance and the final filtration of the bulk drug substance) aspects of process transfer. Read more here.
Lonza in the Press
Atul Mohindra, Head of R&D Biologics, talks about challenges in the industry and data integrations. Return on investments proves to be hard to show, in addition to resources needed for training and operations adjustment. Read more here.
Discover how our recent acquisitions are enhancing our capabilities and offerings in the biopharmaceutical landscape. By acquiring Synaffix B.V., we now provide our customers with a more integrated bioconjugates solution, leveraging Synaffix’s innovative payload and site-specific linker technologies.
Additionally, our March 2024 agreement to acquire Roche’s manufacturing facility in Vacaville, CA, will significantly expand our capacity to meet the increasing global demand for large-scale mammalian manufacturing. Dive into the details of these strategic moves and learn how we're going beyond science to become true partners.
“Over the past two years, Lonza has significantly continued to strengthen its development and manufacturing network as well as its technology portfolio to better support customers from the earliest stages of development to market,” says Jean-Christophe Hyvert, President, Lonza Biologics." Read more here.
Customer Case Study
This article explores how Surrozen selected Lonza as its CDMO partner, highlighting the importance of expertise, flexibility and collaboration. Learn how Lonza’s capabilities have supported Surrozen in developing these first-in-class molecules, overcoming challenges, and preparing for clinical trials. Read more here.
Thank you for reading. Remember to subscribe so you never miss our monthly updates.
If you'd like to find out more about Lonza Biologics, you can visit our website or contact one of our team of experts.
Senior Manager - Imports & Exports
7 个月Impressive , I'm keen to join you and implement my ideas for a better future of our planet Earth, and develop a sustainable Logistics framework